Product
BAY2757556
Aliases
BAY2757556 (Larotrectinib, Vitrakvi), LOXO-101
1 clinical trial
1 indication
Indication
NTRK Fusion Positive Solid TumorsClinical trial
A Study to Learn How Well the Drug Larotrectinib Works in Adults With Different Solid Cancers With a Change in the Genes Called NTRK FusionStatus: Active (not recruiting), Estimated PCD: 2025-07-20